Off-label studies on tofacitinib in dermatology: a review

Tegtmeyer, Kyle; Zhao, Jeffrey; Maloney, Nolan J.; Atassi, Giancarlo; Beestrum, Molly; Lio, Peter A.

doi:10.1080/09546634.2019.1673877

Cited by 30 publications

(31 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another promising class of medications act by inhibiting JAK1, JAK2 and JAK3, thereby blocking cytokine-mediated signalling via the JAK-STAT pathway, which plays an important role in immunoregulation and normal cell growth. This class includes baricitinib (anti-JAK1/2), upadacitinib (anti-JAK1) and abrocitinib (anti-JAK2), all of which are promising oral treatments for various dermatological conditions including AD [30][31][32]. We are certainly at the dawn of a therapeutic revolution in the field!…”

Section: Of the Therapies Currently Being Developed Which Do You Find Particularly Promising For Improving Patient Care?mentioning

confidence: 99%

At the Dawn of a Therapeutic Revolution for Atopic Dermatitis: An Interview with Dr Anne-Claire Fougerousse

Fougerousse

2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

France, and scientific coordinator of a French network of dermatologists and allergists (Re-soEczema). The focus of her work is to improve the care of adolescent and adult patients with atopic dermatitis (AD), a chronic, pruritic inflammatory skin disease that substantially impacts patient quality of life. In this interview, Dr Fougerousse provides an overview of the clinical presentation of adult patients with AD and describes available treatments. Today, topical agents like emollients and corticosteroids are the mainstay of AD therapy, and patients with lesions that are resistant to optimally administered topical treatment can also receive phototherapy or systemic therapy with ciclosporin. Dr Fougerousse discusses her hopes for the future of AD therapy with the recent development of biologicals like dupilumab, which may provide improvements in clinical outcomes and quality of life for patients with moderate-to-severe AD. In the next few years, the therapeutic arsenal for AD will likely expand to include more systemic therapies providing sustained symptom control. The real challenge will be to ensure that the maximum number of patients with AD achieve clinical benefits from these new treatments.

show abstract

Section: Of the Therapies Currently Being Developed Which Do You Find Particularly Promising For Improving Patient Care?mentioning

confidence: 99%

At the Dawn of a Therapeutic Revolution for Atopic Dermatitis: An Interview with Dr Anne-Claire Fougerousse

Fougerousse

2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…12 Tofacitinib diberikan 2 kali sehari dengan dosis 5-10 mg. Efek samping yang mungkin ditimbulkan antara lain supresi sumsum tulang, infeksi saluran napas atas, nasofaringitis, infeksi (bakteri, virus, jamur, terutama pneumonia, selulitis dan herpes zoster), keganasan (limfoma, paru, dan payudara) dan diare. 16 Terdapat 2 studi fase III (OPT Pivotal 1 dan OPT Pivotal 2) yang menentukan efektivitas dan keamanan tofacitinib oral dosis 5 mg dan 10 mg dua kali sehari dibandingkan dengan plasebo pada pasien dengan psoriasis plak derajat sedang hingga berat. Pada OPT Pivotal 1 dan OPT Pivotal 2, didapatkan 745 pasien menerima tofacitinib 5 mg, 741 menerima tofacitinib 10 mg, dan 373 menerima plasebo.…”

Section: Tofacitinibunclassified

Perkembangan Terkini Terapi Sistemik Psoriasis

Sutanto¹,

Budianti²

2021

J. Kdokt Meditek

View full text Add to dashboard Cite

Psoriasis merupakan penyakit inflamasi kulit akibat aktivasi terhadap sistem imun bawaan dan adaptif. Etiopatogenesis psoriasis merupakan proses kompleks dan multifaktorial, yang dipengaruhi oleh faktor genetik dan lingkungan seperti stres, trauma, dan infeksi. Pada pasien dengan psoriasis kategori sedang hingga berat dan lesi lokalisata di area skalp, wajah, kuku, telapak tangan dan kaki, serta genital merupakan indikasi untuk pemberian terapi dengan obat sistemik. Saat ini terdapat berbagai pilihan terapi sistemik yang tersedia yaitu obat sistemik konvensional, terapi small molecules, obat biologik, dan biosimilarnya yang terdiri atas inhibitor TNF-α, inhibitor IL-12/23, inhibitor IL-17, dan inhibitor IL-23. Selama dekade terakhir, tata laksana psoriasis telah mengalami pergeseran paradigma yaitu obat biologik dan biosimilarnya mulai menjadi pilihan utama karena telah terbukti memiliki efektivitas baik, dengan efek samping minimal. Tinjauan pustaka ini membahas perkembangan terapi sistemik psoriasis terkini sehingga diharapkan dapat memberikan acuan untuk memilih terapi yang tepat, efektif, dan aman untuk pasien psoriasis.

show abstract

“…A recently developed Janus kinase inhibitor (JAK-inhibitor) has demonstrated an impressive hair regrowth in long-term alopecia universalis [7,8]. Namely, tofacitinib (TFB)-an FDA-approved immunosuppressant against rheumatoid arthritis, psoriasis arthritis, and ulcerative colitis [9], which inhibits JAK 1 and 3, has shown promising treatment progress on human and mice [10][11][12][13]. However, continuous treatment is necessary to gain a possible persistent success in hair regrowth [12,13].…”

Section: Introductionmentioning

confidence: 99%

“…Namely, tofacitinib (TFB)-an FDA-approved immunosuppressant against rheumatoid arthritis, psoriasis arthritis, and ulcerative colitis [9], which inhibits JAK 1 and 3, has shown promising treatment progress on human and mice [10][11][12][13]. However, continuous treatment is necessary to gain a possible persistent success in hair regrowth [12,13]. Unfortunately, long-term systemic treatment with TFB can cause a broad and severe spectrum of adverse effects due to the wide bioactive range of such JAKs [14].…”

Section: Introductionmentioning

confidence: 99%

Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases

Christmann

Wilzopolski

et al. 2020

Pharmaceutics

View full text Add to dashboard Cite

Tofacitinib (TFB), a Janus kinase inhibitor, has shown excellent success off-label in treating various dermatological diseases, especially alopecia areata (AA). However, TFB’s safe and targeted delivery into hair follicles (HFs) is highly desirable due to its systemic adverse effects. Nanoparticles (NPs) can enhance targeted follicular drug delivery and minimize interfollicular permeation and thereby reduce systemic drug exposure. In this study, we report a facile method to assemble the stable and uniform 240 nm TFB loaded squalenyl derivative (SqD) nanoparticles (TFB SqD NPs) in aqueous solution, which allowed an excellent loading capacity (LC) of 20%. The SqD NPs showed an enhanced TFB delivery into HFs compared to the aqueous formulations of plain drug in an ex vivo pig ear model. Furthermore, the therapeutic efficacy of the TFB SqD NPs was studied in a mouse model of allergic dermatitis by ear swelling reduction and compared to TFB dissolved in a non-aqueous mixture of acetone and DMSO (7:1 v/v). Whereas such formulation would not be acceptable for use in the clinic, the TFB SqD NPs dispersed in water illustrated a better reduction in inflammatory effects than plain TFB’s aqueous formulation, implying both encouraging good in vivo efficacy and safety. These findings support the potential of TFB SqD NPs for developing a long-term topical therapy of AA.

show abstract

Off-label studies on tofacitinib in dermatology: a review

Cited by 30 publications

References 78 publications

At the Dawn of a Therapeutic Revolution for Atopic Dermatitis: An Interview with Dr Anne-Claire Fougerousse

At the Dawn of a Therapeutic Revolution for Atopic Dermatitis: An Interview with Dr Anne-Claire Fougerousse

Perkembangan Terkini Terapi Sistemik Psoriasis

Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases

Contact Info

Product

Resources

About